宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

香港特别行政区成立纪念日休市 06-30 16:08:05

3.870

+0.090

+2.38%

最高3.900	最低3.710	成交量86.16万
今开3.840	昨收3.780	日振幅5.03%
总市值16.64亿	流通市值16.22亿	总股本4.30亿
成交额328.57万	换手率0.21%	流通股本4.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.87,"timestamp":1782806885629,"preClose":3.78,"halted":0,"volume":861600,"delay":0,"changeRate":0.02380952380952389,"floatShares":419000000,"shares":430000000,"eps":-0.53,"marketStatus":"香港特别行政区成立纪念日休市","change":0.09,"latestTime":"06-30 16:08:05","open":3.84,"high":3.9,"low":3.71,"amount":3285730,"amplitude":0.050265,"askPrice":3.92,"askSize":3200,"bidPrice":3.87,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-0.589757,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":7,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.78,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":0.7242527151010032,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"1166937192","title":"宜明昂科-B：6月26日回购93,400股，耗资约34.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166937192","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166937192?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:37","pubTimestamp":1782466673,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月26日发布翌日披露报表，宣布在香港联交所场内进行股份回购。本次回购牵涉93,400股H股，约占公告前公司已发行股本的0.0223%。回购价格介乎每股3.60港元至3.74港元，涉资合共342,122港元。据公告，宜明昂科-B此前于2026年5月28日通过股份回购授权，授权总数为43,150,769股。截至目前，公司已根据相关授权累计回购1,441,800股，占回购授权获批准当日已发行股本约0.334%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：6月26日回购93,400股，耗资约34.21万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646803184","title":"宜明昂科-B(01541)6月25日斥资47.44万港元回购13.36万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646803184","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646803184?lang=zh_cn&edition=full","pubTime":"2026-06-25 21:00","pubTimestamp":1782392417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，该公司于2026年6月25日斥资47.44万港元回购13.36万股股份，每股回购价格为3.44-3.64港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157579957","title":"宜明昂科-B回购13.36万股股份，总额约47.44万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157579957","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157579957?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:56","pubTimestamp":1782392173,"startTime":"0","endTime":"0","summary":"宜明昂科-B于2026年6月25日公告，当日于香港联交所场内回购普通股H股共133,600股，约占此前已发行股份总数419,262,505股的0.0319%。每股回购价格介乎港币3.44元至3.64元，合计支付约47.44万港元。股份回购完成后，公司已发行股本变更为419,128,905股，库藏股增至1,348,400股。此次回购经公司于2026年5月28日通过的回购授权批准，授权可回购股份总数为43,150,769股。公司确认其回购行为符合香港联合交易所有限公司证券上市规则及相关法律规定。公告由执行董事、联席公司秘书关梅签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购13.36万股股份，总额约47.44万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139040405","title":"宜明昂科-B回购29.14万股，耗资约109.60万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139040405","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139040405?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:55","pubTimestamp":1782294947,"startTime":"0","endTime":"0","summary":"根据公告，公司当日共回购29.14万股H股，占回购前公司已发行股本约0.0695%，回购价格介乎每股3.69港元至3.80港元，总金额约为109.60万港元。本次回购完成后，公司已发行股本数量为419,262,505股，库藏股数量为1,214,800股，已发行股份总数仍为420,477,305股。公告同时披露，根据规定，在本次回购后30日内公司将暂停执行任何新增股份发行或售出、转让任何库藏股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购29.14万股，耗资约109.60万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891360","title":"宜明昂科-B(01541)6月24日斥资109.6万港元回购29.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891360","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891360?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:55","pubTimestamp":1782294930,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年6月24日斥资109.6万港元回购29.14万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004821","title":"港股异动 | 宜明昂科-B(01541)早盘涨超7% IMM2510有望填补后线肺鳞癌治疗的临床空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645004821?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:21","pubTimestamp":1782181305,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B早盘涨超7%，截至发稿，涨2.63%，报3.9港元，成交额179.63万港元。消息面上，宜明昂科宣布，近期在ASCO 2026年会上以壁报形式公布IMM2510治疗IO经治晚期肺鳞癌最新进展。数据显示，IMM2510在经免疫治疗进展的晚期肺鳞癌患者中，不仅疗效显著，更展现出区别于同类产品的优异安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","01541","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644081116","title":"宜明昂科-B(01541)：附属获嘉兴昶新增资32.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644081116","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644081116?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:17","pubTimestamp":1781792253,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，于2026年6月18日，本公司、嘉兴昶新及目标公司宜明凯尔生物医药技术(上海)有限公司订立增资协议，据此，嘉兴昶新同意认购目标公司新增资本人民币32.5万元，即目标公司新增注册资本的14.0%，对价为人民币32.5万元。增资完成后，本公司及嘉兴昶新于目标公司的股权将分别为80.0%及20.0%。嘉兴昶新为就目标公司设立的员工持股平台。当目标公司采纳有关员工激励计划时，本公司将遵守上市规则项下相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123651224","title":"宜明昂科-B拟斥资8750万港元认购维港投资理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1123651224","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123651224?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:51","pubTimestamp":1781707865,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药（上海）股份有限公司（01541.HK）宣布，计划动用8750万港元自有资金，认购由维港投资提供的一款理财产品。此举旨在提升公司闲置资金的利用效率，寻求在风险可控的前提下获取稳健的财务回报。公司管理层表示，本次投资决策经过了审慎评估，符合公司资金管理策略，不会影响日常运营及主营业务发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107429587","title":"宜明昂科-B6月16日回购16.32万股股份，总额约59.25万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107429587","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107429587?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:15","pubTimestamp":1781619359,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司2026年6月16日公告显示，公司当日于香港联交所场内回购股份16.32万股，约占现有已发行股本的0.0389%。本次回购价格区间为每股3.56港元至3.64港元，总代价为59.25万港元。公司此前于2026年5月28日通过有关股份购回授权，获准回购约4,315.08万股，截至目前合计已回购92.34万股，占授权数量的约0.214%。公司确认本次回购已严格遵守香港联合交易所有限公司证券上市规则及其他相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B6月16日回购16.32万股股份，总额约59.25万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763332","title":"宜明昂科-B(01541)6月16日斥资59.25万港元回购16.32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643763332?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:15","pubTimestamp":1781619340,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年6月16日斥资59.25万港元回购16.32万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127924127","title":"宜明昂科-B：6月12日回购2,600股，耗资约8,722港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127924127","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127924127?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:21","pubTimestamp":1781263295,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月12日发布翌日披露报表，报告显示该公司在香港联交所场内回购普通股2,600股。此次回购股份占2026年6月11日公司现有已发行股本约0.0006%，每股回购价介乎3.35港元至3.36港元，总投入金额约8,722港元。该公司于2026年5月28日获股东大会授权回购最多43,150,769股，迄今已合计回购760,200股，占授权当日公司已发行股本的0.1762%。公司同时确认其回购行为符合香港联交所证券上市规则及相关法律与监管规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B：6月12日回购2,600股，耗资约8,722港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148225904","title":"宜明昂科-B回购2.30万股股份，总额约7.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148225904","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148225904?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:46","pubTimestamp":1781174779,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月11日发布公告，披露在香港联合交易所场内回购部分H股股份。公告显示，该公司于2026年6月11日回购股份数量为23,000股，约占本次回购前已发行股本的0.0055%。回购完成后，公司已发行股份总数更新为419,719,705股，库藏股数量增至757,600股，合计股本数量为420,477,305股。另外，公司指出，本次回购后任何新股发行或库藏股出售在2026年7月11日之前受上市规则所规定的暂止期限制。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购2.30万股股份，总额约7.24万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162486730","title":"宜明昂科-B回购52,800股股份，总额约16.93万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162486730","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162486730?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:46","pubTimestamp":1781091997,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月10日发布翌日披露报表，公告公司于2026年6月10日在香港联交所场内回购52,800股H股普通股股份。此次回购股份数量占该事件前现有已发行股本约0.0126%，每股价格介乎港币3.12元至3.27元，合共耗资约16.93万港元。本次回购完成后，宜明昂科-B已发行股份总数为420,477,305股，其中419,742,705股为已发行股份、734,600股为库存股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购52,800股股份，总额约16.93万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423403","title":"宜明昂科-B(01541)6月10日斥资16.93万港元回购5.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423403","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642423403?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:44","pubTimestamp":1781091862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年6月10日斥资16.93万港元回购5.28万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174897767","title":"宜明昂科-B：6月9日回购41.6万股，耗资约129.37万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174897767","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174897767?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:26","pubTimestamp":1781000801,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司6月9日向香港联合交易所提交翌日披露报表，公布进行股份回购。据公告，6月9日，公司于香港联交所场内回购416,000股H股，占回购前已发行股份约0.099%。本次回购每股价格介乎3.03港元至3.20港元之间，回购股份的加权平均每股价格为3.1099港元，总涉资1,293,708港元。本次回购完成后，公司于截止6月9日的已发行股份为419,795,505股，库存股份为681,800股，合计420,477,305股。截至目前，已累计购回股份681,800股，占获授权数量约0.158%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：6月9日回购41.6万股，耗资约129.37万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185406218","title":"宜明昂科-B 6月8日回购26.58万股，耗资约82.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185406218","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185406218?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:21","pubTimestamp":1780928516,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司（宜明昂科-B）于2026年6月8日在香港联交所回购H股股份，共回购26.58万股，占该次回购前已发行股份（不含库藏股）总数的约0.0632%。每股回购价格介乎每股3.04港元至3.27港元，合计支付约82.78万港元。回购完成后，公司已发行股份总数维持4.20亿股，其中外部流通股为4.20亿股，库藏股26.58万股。根据股东于2026年5月28日通过的回购授权，公司可回购的股份总数为4315.08万股，本次回购数量约占授权总额的0.0616%。\n公司同时确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由执行董事、联席公司秘书关梅签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 6月8日回购26.58万股，耗资约82.78万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641480399","title":"宜明昂科-B(01541)6月8日斥资82.78万港元回购26.58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641480399","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641480399?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:19","pubTimestamp":1780928376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年6月8日，该公司斥资82.78万港元回购26.58万股股份，每股回购价3.04-3.27港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641712197","title":"港股异动 | 宜明昂科-B(01541)涨超7% IMC-002治疗中重度SLE Ib/II期初步数据以壁报形式于EULAR 2026公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2641712197","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641712197?lang=zh_cn&edition=full","pubTime":"2026-06-05 14:19","pubTimestamp":1780640370,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002，在2026年欧洲抗风湿病联盟年会上以壁报形式公布了其针对中重度活动性系统性红斑狼疮患者的Ib/II期临床试验最新初步结果。据介绍，IMC-002是一款靶向CD20和CD47的双特异性融合蛋白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4077","BK4585","01541","SLE","BK1161","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178023372","title":"宜明昂科-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178023372","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178023372?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:47","pubTimestamp":1780476433,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月3日发布2026年5月股份变动月报表。该报告期截至2026年5月31日，公司股本结构总体维持稳定，未发生新增发行、购回或注销股份的事项。本次公告显示，公司注册股本本月底合计为人民币431,507,695元，较上月底无变化。其中，上市H股420,477,305股，非上市股份11,030,390股。本次公告由执行董事、联席公司秘书关梅签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990015","title":"港股异动 | 宜明昂科-B(01541)涨超7% 公布IMM2510治疗IO经治晚期肺鳞癌积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990015","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990015?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:12","pubTimestamp":1780384337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨7.36%，报3.21港元，成交额2670.97万港元。消息面上，6月1日，宜明昂科宣布，公司自主研发的VEGF×PD-L1双靶点药物珀维拉芙普α（IMM2510）在2026年美国临床肿瘤学会（ASCO）年会上正式公布了其I期临床研究数据（摘要号：8580）。数据显示，IMM2510在经免疫治疗（IO）进展的晚期肺鳞癌患者中，不仅疗效显著，更展现出区别于同类产品的优异安全性。公司指，基于I期研究展现出的积极数据及暴露-效应分析结果，研究已确定20mg/kg Q2W为II期推荐剂量（RP2D），后续III期临床研究正在计划中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","01541","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0026},{"period":"1month","weight":0.3208},{"period":"3month","weight":-0.2558},{"period":"6month","weight":-0.3362},{"period":"1year","weight":-0.6775},{"period":"ytd","weight":-0.3362}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}